Journal
INTEGRATIVE BIOLOGY
Volume 2, Issue 9, Pages 397-407Publisher
OXFORD UNIV PRESS
DOI: 10.1039/c0ib00008f
Keywords
-
Categories
Funding
- BBSRC with Wyeth UK
- British Heart Foundation
- Wellcome Trust
Ask authors/readers for more resources
Vascular endothelial growth factor A (VEGF-A) and its cognate receptors are central to the regulation of angiogenesis in both physiological and pathological states. In cancer, local tumour hypoxia stimulates VEGF-A synthesis and VEGF-A levels are subsequently elevated in a wide variety of cancers. VEGF-A thus has enormous potential as a diagnostic and prognostic biomarker of disease status. The justification of VEGF-A as a biomarker has not yet been achieved, primarily due to our lack of understanding of its multiple splice variants and its spatio-temporal distribution. Here we highlight how recent technological advancements and kinetic-dynamic modelling could be used towards validating VEGF-A as a biomarker for clinical use in human disease management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available